Cost - effectiveness and Cost - utility of CinnoVex versus ReciGen in Patients with Relapsing - Remitting Multiple Sclerosis in Iran
Autor: | Ramin Ravangard, Mehdi Rezaee, Khosro Keshavarz, Sadegh Izadi, Afshin Borhani-Haghighi |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
business.industry Cost effectiveness Multiple sclerosis General Medicine Disease medicine.disease 03 medical and health sciences 0302 clinical medicine Quality of life Relapsing remitting Cost utility Physical therapy Medicine In patient 030212 general & internal medicine business 030217 neurology & neurosurgery Cost database |
Zdroj: | Shiraz E-Medical Journal. |
ISSN: | 1735-1391 |
Popis: | Background: Multiple Sclerosis (MS) is a chronic and inflammatory disease that can affect the patients’ quality of life and impose many costs on them. Several types of medicine are used to change the course of the disease, treat disease - related attacks, and treat the symptoms of multiple sclerosis. Objectives: The aim of this study was to determine and compare the cost-effectiveness and cost - utility of CinnoVex versus ReciGen as the first line treatment in patients with relapsing-remitting multiple sclerosis in Iran, Fars province, in 2016. Methods: This study was a cost - effectiveness and cost - utility study, in which a Markov model was used. A sample of 178 patients with MS was randomly selected. The costs were summed up from the societal perspective, and the study outcomes were QALY and the mean of relapse was avoided. To collect the required data, the cost data collection form, Kurtzke Expanded Disability Status Scale, and EQ - 5D questionnaire were used. To analyze the data collected, the TreeAge Pro 2011 and Excel 2010 software were used as well. Results: The results showed that the mean cost for ReciGen and CinnoVex patients were 349.84 and 289.92 USD, respectively. In addition, the QALY means were 0.291 and 0.297 and the means of relapse avoided were 0.309 and 0.239 for ReciGen and CinnoVex patients, respectively. The one - way sensitivity analysis showed that the results of the model were sensitive to effectiveness and utility of both medicines, but had little sensitivity to other parameters. Conclusions: According to the results, ReciGen was more cost - effective in terms of relapse avoided and CinnoVex was more cost - effective in terms of QALY. Therefore, ReciGen and CinnoVex can be the preferred options for physicians and for health policymakers and managers, respectively. |
Databáze: | OpenAIRE |
Externí odkaz: |